The GABAergic projection neurons in the substantia nigra pars reticulata (SNr) are key basal ganglia output neurons. The activity of these neurons is critically influenced by the glutamatergic projection from the subthalamic nucleus ( 
Introduction
The GABAergic projection neurons are the main neuronal type in the substantia nigral pars reticulata (SNr), one of the two output nuclei of the basal ganglia (Bolam et al., 2000; Deniau et al., 2007) . These GABA neurons fire tonic high-frequency spikes generated by a complex interaction of intrinsic ion channels (Atherton and Bevan, 2005; Zhou et al., 2008) . This tonic firing is sculpted into more meaningful motor control signals by synaptic inputs (Hikosaka et al., 2000; Zhou and Lee, 2011) . One such synaptic input is the glutamatergic input from the subthalamic nucleus (STN) (Bevan et al., 1994; Parent and Hazrati, 1995; Sato et al., 2000; . This glutamatergic projection provides a powerful excitatory drive that can increase the firing rate and alter the firing pattern such as inducing burst firing in SNr GABA neurons (Galati et al., 2006; Shen and Johnson, 2006; Ammari et al., 2010; Wilson and Bevan, 2011) . Evidence indicates that increased firing rates and excessive bursting in SNr GABA neurons may contribute to the motor symptoms in experimental Parkinson's disease (PD) models and PD patients (Ryan and Sanders, 1993; Murer et al., 1997; Tseng et al., 2000; Steigerwald et al., 2008; Wichmann and Dostrovsky, 2011) . STN lesion or functional inactivation that removes or alters the STN3 SNr projection alleviates PD motor symptoms accompanied by decreased burst firing in SNr GABA neurons (Perlmutter and Mink, 2006; Maltête et al., 2007; Gubellini et al., 2009; Follett et al., 2010) .
The preclinical and clinical evidence presented in the preceding section suggests that the STN-originated glutamatergic projection exerts a critical control over the intensity and pattern of SNr GABA neuron spiking activity. Consequently, mechanisms that regulate this STN3 SNr projection, either at the cell body in the STN or at the axon terminal in the SNr, may influence basal ganglia output and movement control. One potential mechanism is 5-HT-mediated regulations. Anatomical studies have shown that although both the STN and the SNr receive 5-HT innervation originating in the dorsal raphe nucleus, the 5-HT innervation in the SNr is particularly dense with the 5-HT axon terminal density being twice that in the STN (Steinbusch, 1981; Moukhles et al., 1997; Parent et al., 2010 Parent et al., , 2011 Hashemi et al., 2011) . Like the intense 5-HT innervation, histochemical and ultrastructural studies have also demonstrated an intense expression of inhibitory 5-HT1B receptors in the axons but not in the somatodendritic areas in the SNr (Voigt et al., 1991; Maroteaux et al., 1992; Boschert et al., 1994; Sari et al., 1999; Riad et al., 2000; Sari, 2004) . A lesion study indicated that ϳ50% of 5-HT1B receptors in the SNr was on striatonigral axons while the sources of the remaining 50% of the receptors were not known (Sari et al., 1999) . Since STN neurons have a strong expression of 5-HT1B receptor mRNA, we reason that the STN3 SNr axon terminals may express 5-HT1B receptors. Given the intense 5-HT innervation in the SNr, we hypothesize that these presynaptic 5-HT1B receptors may gate the STN3 SNr glutamatergic projection at the axon terminal level and control the intensity of glutamatergic excitation in these basal ganglia output neurons.
Materials and Methods

Electrophysiology
Preparation of brain slices. Wild-type, 20-to 27-d-old male and female C57BL mice were used. All procedures were performed in accordance with Institutional Animal Care and Use Committee of The University of Tennessee Health Science Center and followed the guidelines of the National Institutes of Health. The procedures to prepare 10°angular sagittal slices containing the SNr, the STN, and the striatum (see Fig. 1A ) have been described in detail (Wallmichrath and Szabo, 2002; Beurrier et al., 2006; Ammari et al., 2010) . Briefly, mice were killed by decapitation under deep anesthesia, and brains were quickly dissected out and immediately immersed in oxygenated ice-cold cutting solution containing the following (in mM): 220 glycerol, 2.5 KCl, 1.25 NaH 2 PO 4 , 25 NaHCO 3 , 0.5 CaCl 2 , 7 MgCl 2 , and 20 D-glucose. Parasagittal slices (300 m thick) were cut using a Leica Zero Z VT1200S vibratome (Leica Microsystems) at an angle of 10°. The brain slices were transferred to a holding chamber at 34°C for 30 min in a standard artificial CSF (ACSF) containing the following (in mM): 125 NaCl, 2.5 KCl, 25 NaHCO 3 , 1.25 NaH 2 PO 4 , 2.5 CaCl 2 , 1.3 MgCl 2 , and 10 D-glucose that was continuously bubbled with 95% O 2 and 5% CO 2 . After this initial 30 min incubation at 34°C, the brain slices were kept at room temperature (25°C).
Whole-cell patch-clamp recording. Slices were placed in a recording chamber mounted on the microscope stage and continuously perfused at 2 ml/min with the standard ACSF saturated with 95% O 2 and 5% CO 2 . Recordings were made at 30°C (TC 324B temperature controller; Warner Instruments) under visual guidance of a video microscope (an Olympus BX51WI and a Zeiss Axiocam MRm digital camera) equipped with Nomarski optics and a 60ϫ water-immersion lens (Fig. 1B) . Patch pipettes were pulled from borosilicate glass capillary tubing (KG-33, 1.1 mm inner diameter, 1.65 mm outer diameter; King Precision Glass) using a PC-10 puller (Narishige) and had resistances of 1.5-2.5 M⍀ when filled with one of the following intracellular solutions. A CsCl-based intracellular solution containing the following (in mM): 135 CsCl, 0.5 EGTA, 10 HEPES, 2 Mg-ATP, 0.2 Na-GTP, and 4 Na 2 -phosphocreatine, pH 7.25, 280 -290 mOsm was used to record evoked complex EPSCs and miniature EPSCs (mEPSCs) in voltage-clamp recording mode. A KCl-based intracellular solution containing the following (in mM): 135 KCl, 0.5 EGTA, 10 HEPES, 2 Mg-ATP, 0.2 Na-GTP, and 4 Na 2 -phosphocreatine, pH 7.25, 280 -290 mOsm was used to record burst spiking activity in current-clamp recording mode. When recording evoked complex EPSCs, the Na ϩ channel blocker lidocaine N-ethyl bromide (QX-314, 4 mM) was added to the intracellular solution to block Na spikes. mEPSCs were recorded in the presence of tetrodotoxin (TTX, 1 M) to block action potentials. All recordings were made in the presence of 100 M picrotoxin to block GABA A receptors.
Electrical stimulation to evoke synaptic responses. A bipolar tungsten electrode (Microprobes) was placed in the STN to activate STN3 SNr glutamatergic projection and evoke complex EPSCs in SNr GABA neurons. A single pulse (0.2 ms duration) was generated by a Master-8 pulse generator (AMPI) and delivered at 0.05 Hz. The stimulation intensity was from 100 to 300 A. To evoke monosynaptic EPSC in SNr GABA neurons, the bipolar tungsten stimulating electrode was placed within the SNr; paired pulses or a train of 10 pulses with an interpulse interval of 50 ms was generated by the Master-8 and delivered at 0.05 Hz with the stimulation intensity ranging from 10 to 50 A.
Data acquisition and analysis. A MultiClamp 700B amplifier, pClamp 9.2 software, and Digidata 1322A interface (Molecular Devices) were used to acquire data. For voltage-clamp recording, cells were held at Ϫ70 mV. Access resistance was monitored by a 10 mV, 50 ms pulse before every evoked EPSC. Cells in which the access resistance increased by Ͼ15% were discarded. Liquid junction potential (4.8 mV for CsCl-based solution and 4.2 mV for KCl-based solution) was not corrected.
Complex EPSCs were quantified by measuring their integrated area or charge transfer using pClampfit 9.2 software. Averages of 10 consecutive complex EPSCs before or during drug administration were used to evaluate drug response. The complex EPSC area after drug administration was normalized to the predrug baseline value. Monosynaptic EPSCs were evoked by a paired pulse protocol or a 10-pulse train stimulating protocol with the stimulating electrode positioned in the SNr. The peak amplitudes of the monosynaptic EPSCs were measured using pClampfit 9.2 software. Averages of 10 consecutive monosynaptic EPSCs before or during drug administration were used to evaluate baseline and drug response, respectively. Paired pulse ratio (PPR) (for the monosynaptic EPSCs evoked by a paired pulse protocol) was calculated by dividing the peak amplitude of the second monosynaptic EPSCs by the peak amplitude of the first monosynaptic EPSCs. EPSC n /EPSC 1 (for the monosynaptic EPSCs evoked by the10-pulse train stimulating protocol) was calculated by dividing the peak amplitude of the nth monosynaptic EPSC by the peak amplitude of the first monosynaptic EPSCs. The burst firing in SNr GABA neurons evoked by STN stimulation was quantified by measuring the average firing frequency during the 100 ms immediately after stimulation artifacts. mEPSCs were detected and analyzed by MiniAnalysis.
Drugs. All drugs were made into stock solutions in ddH 2 O or dimethylsulfoxide. Stock solutions of drugs were diluted at least 1:1000 to the desired concentration in ACSF immediately before their application. Aminophosphonovalerate (APV), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), QX-314, 5-HT, picrotoxin, CP93129, NAS-181, 8-OH-DPAT, tetrodotoxin (TTX), and WAY100135 were purchased from either Tocris Bioscience or Sigma-Aldrich. Drugs were mostly bath applied. In Figure 10 , 5-HT1B agonist CP93129 was puff applied using a Picospritzer and puff pipettes with a tip diameter ϳ4 m. In the SNr, the puff pipette was positioned above the tissue surface and 50 -100 m away from the neuron being recorded. In the STN, the puff pipette was positioned above the tissue surface and between the two poles of the stimulating electrode. The pressure pulse was 5 PSI and 200 ms. The pulse started 1 s before electrical synaptic stimulation to allow the drug to diffuse. Cells included in this report had stable baseline activity and druginduced responses, thus excluding potential effects from the leaked drug.
Statistics. Data are reported as mean Ϯ SE. The paired t test was used to make comparisons of evoked events before and during drug administration. Cumulative amplitude and frequency distributions of mEPSCs were compared using the Kolmogorov-Smirnov (K-S) test. One-way ANOVA with post hoc Bonferroni test and repeated-measures ANOVA were also used when needed. The required computation was performed using StatMost or SPSS 20. p value Ͻ0.05 was considered statistically significant.
Immunohistochemistry
The brains were fixed in 4% paraformaldehyde at 4°C overnight. Sagittal brain sections (50 m in thickness) were cut on a Leica VT1200S vibratome. The sections then were processed for immunofluorescence detection of serotonin transporter (SERT). The free-floating sections were incubated with 2% fat-free milk, 1% bovine serum albumin (BSA), and 0.4% Triton X-100 in the PBS for 1 h at room temperature to block nonspecific binding and permeate the cell membrane, respectively. After thorough rinsing, the free-floating sections were incubated for 48 h at 4°C with the primary antibody (see below) and then rinsed in a PBS three times for 5 min each, followed by incubating with the secondary antibody (see below) for 3 h at room temperature in the dark. Both the primary and secondary antigen-antibody reactions occurred in the PBS containing 3% normal donkey serum, 1% BSA, and 0.1% Triton X-100. The primary antibody was a polyclonal SERT antibody raised in goat (Santa Cruz Biotechnology; diluted at 1:800). The secondary antibody was a donkey anti-goat IgG antibody, conjugated with red Alexa Fluor 568 (diluted at 1:200). Fluorescence images were acquired on a Zeiss 710 confocal laser scanning microscope.
Results
STN stimulation evokes complex EPSCs in SNr GABA neurons
The main neuron type in the SNr is the GABA projection neurons that fire spontaneously ϳ10 Hz under in vitro conditions (Atherton and Bevan, 2005; Ding et al., 2011a,b; Zhou and Lee, 2011) . The SNr also contains sparse dopamine neurons that fire spontaneously ϳ1.5 Hz under similar in vitro conditions (Zhou et al., 2006; Ding et al., 2011a,b) . Thus, we first briefly recorded action potentials in a cell-attached mode in our angular sagittal brain slices containing SNr and STN ( Fig. 1A-C) . Neurons in the SNr with a spontaneous firing rate Ն5 Hz were presumed to be GABA neurons. After cell identification, we proceeded to whole-cell recording mode and started STN stimulation to activate STN3 SNr glutamatergic projection. As shown in Figure 1D , focal stimulation in the STN consistently evoked long-lasting, complex EPSCs in SNr GABA neurons, likely resulting from recurrent polysynaptic excitatory interactions among STN neurons, as reported by Shen and Johnson (2006, 2012) and Ammari et al. (2010) . These evoked complex EPSCs and also the spontaneous EPSCs (sEPSCs) were blocked by bath-applied CNQX (10 M) and APV (20 M) (Fig. 1D ,E), indicating that these complex EPSCs and sEPSCs were mediated by ionotropic glutamate receptors.
5-HT inhibits STN3 SNr complex EPSCs
To determine the potential 5-HT regulation of the STN3 SNr glutamatergic transmission, we first examined the effect of bathapplied 5-HT on the STN-triggered complex EPSCs in SNr GABA neurons. Bath-applied 5-HT should activate 5-HT receptors on both STN neuron cell bodies and axon terminals. Thus, the potential 5-HT effect on the complex EPSCs in SNr neurons should reflect the summation of potential somatic and presynaptic effects, if any. We found that bath application of 10 M 5-HT consistently inhibited the complex EPSCs, the amplitude in particular while the duration was less affected (Fig.  2 A, B) . To quantify this inhibition, we calculated the area or the charge transfer of the complex EPSCs. In eight SNr GABA neurons, 10 M 5-HT reduced the complex EPSC area to 34.2 Ϯ 2.7% of the control, a 66% reduction ( p Ͻ 0.01, paired t test). This inhibitory effect recovered upon washing out 5-HT ( Fig.  2A-C) . By applying 1, 5, 10, 20, 50, and 100 M 5-HT, we determined that 5-HT inhibited the complex EPSCs in a doseresponse manner with an IC 50 of 4.24 M and a Hill coefficient of 1.4, based on fitting the data points to the Hill equation (Fig. 2D ). These results clearly indicated that 5-HT has a net inhibitory effect on the STN3 SNr complex EPSCs. Next, we asked this question: Which type(s) of 5-HT receptors was mediating this inhibitory effect?
5-HT1B agonist CP93129 mimics and 5-HT1B antagonist NAS-181 inhibits the 5-HT effect on STN3 SNr complex EPSCs
Among the known 5-HT receptors, only the 5-HT1 subfamily is inhibitory by coupling to G i/o G-protein (Bockaert et al., 2006; Hannon and Hoyer, 2008; Millan et al., 2008) . Among the brain 5-HT1 receptor subtypes, only 5-HT1A and 5-HT1B receptors are expressed at substantial levels (Bruinvels et al., 1993; Barnes and Sharp, 1999) . 5-HT1B receptors are known to selectively express in axon terminals while 5-HT1A receptors may be expressed at the somata and also axon terminals (Sari et al., 1999; Riad et al., 2000) . Thus, we reasoned that 5-HT may inhibit complex EPSCs by activating primarily 5-HT1B receptors on STN3 SNr axon terminals. To test this possibility, we first examined the effect of the 5-HT1B receptor agonist CP93129 (Li and Bayliss, 1998; Mizutani et al., 2006) . As illustrated in Figure 3 , A1-A3, bath application of 10 M CP93129 reduced the complex EPSC area to 21.27 Ϯ 2.52% of the control, a 79% reduction ( p Ͻ 0.001, paired t test, n ϭ 7 neurons), mimicking the inhibitory 5-HT effect shown in Figure  2 . Furthermore, bath application of 10 M NAS-181, a 5-HT1B receptor antagonist (Mizutani et al., 2006) , blocked the effects of 10 M 5-HT on complex EPSCs (n ϭ 5 neurons; Fig. 3B1 -B3). Together, these results indicated that 5-HT may inhibit the STN3 SNr complex EPSCs through inhibitory 5-HT1B receptors.
To determine whether inhibitory 5-HT1A receptors also contribute to the 5-HT inhibition of the STN3 SNr complex EPSCs, we tested the effect of 8-OH-DPAT, a 5-HT1A receptor agonist (Mizutani et al., 2006) . As shown in Figure 4 , A1-A3, 10 M 8-OH-DPAT had no effect on STN3 SNr complex EPSCs. Similarly, 10 M WAY100135, a 5-HT1A receptor antagonist, also failed to inhibit the effect of 10 M 5-HT on complex EPSCs (Fig.  4B1-B3 ). The fact that 5-HT1A receptor agonist 8-OH-DPAT did not mimic and 5-HT1A receptor antagonist WAY100135 did not block the effect of 5-HT on STN3 SNr complex EPSCs indi- 
, where A is the maximal inhibition, X is the 5-HT concentrations, K is the IC 50 , and n is the Hill coefficient. Each data point represents 4 -8 experiments. **p Ͻ 0.01, paired t test. cates that 5-HT1A receptors do not make detectable contribution to the 5-HT inhibition of STN3 SNr complex EPSCs, further supporting the primary role for 5-HT1B receptors.
5-HT reduces the frequency of mEPSCs in SNr GABA neurons
The results in the preceding sections suggested that 5-HT inhibited the STN3 SNr complex EPSCs by activating 5-HT1B receptors. Next, we asked this question: Where are these 5-HT1B receptors located? Anatomical studies have indicated that 5-HT1B receptors are commonly located on the presynaptic terminals (Boschert et al., 1994; Sari et al., 1999; Riad et al., 2000; Sari, 2004 ). So we reasoned that 5-HT may activate presynaptic 5-HT1B receptors to inhibit the STN3 SNr complex EPSCs. To answer this question, we studied the effect of 5-HT on mEPSCs in SNr GABA neurons, since the frequency of mEPSCs is an indication of vesicular neurotransmitter release, whereas the amplitude of mEPSCs is largely a reflection of postsynaptic glutamate receptors (Sudhof, 2004) . mEPSCs were recorded in the presence of 1 M TTX. Indeed, as illustrated in Figure 5 , A-F, bath application of 10 M 5-HT decreased the frequency of mEPSCs in SNr GABA neurons from 7.51 Ϯ 1.64 to 3.53 Ϯ 0.89 Hz, a 53% decrease ( p Ͻ 0.01, paired t test, n ϭ 7 neurons). In contrast, the amplitude of these mEPSCs was not affected (10.80 Ϯ 0.46 pA and 10.43 Ϯ 0.44 pA for before and during bath application of 5-HT, respectively, p Ͼ 0.05, paired t test, n ϭ 7 neurons). The 5-HT1B receptor agonist CP93129 had similar effects (n ϭ 3 cells). These results indicated that 5-HT inhibited complex EPSCs by activating the inhibitory 5-HT1B receptors on the STN3 SNr axon terminals in the SNr, leading to reduced vesicular neurotransmitter release.
5-HT inhibits monosynaptic STN3 SNr EPSCs in SNr GABA neurons
We further tested the idea of inhibitory presynaptic 5-HT receptors on STN3 SNr axon terminals by studying the effect of 5-HT on monosynaptic EPSCs in SNr GABA neurons evoked by a paired pulse protocol with the stimulating electrode placed in the SNr to avoid activating intra-STN recurrent excitation. As shown in Figure 6 , A1 and B1, bath application of 10 M 5-HT reduced the peak amplitude of the first of the paired EPSCs to 44.4 Ϯ 3.5% of the control, a 56% decrease (p Ͻ 0.01, paired t test, n ϭ 7). Meanwhile, 10 M 5-HT reduced the peak amplitude of the second of the paired EPSCs to a less extent, thus increasing the PPR from 0.83 Ϯ 0.07 under control to 1.21 Ϯ 0.11 during 5-HT application (p Ͻ 0.05, paired t test, n ϭ 7) (Fig. 6A2,B2 ). The 5-HT1B agonist CP93129 had similar effects (n ϭ 4 cells). Since an increased PPR is an indication of inhibition of presynaptic vesicular release (Dittman et al., 2000; Thomson, 2000; Zucker and Regehr, 2002; Fioravante and Regehr, 2011) , these results further suggest a presynaptic 5-HT1B receptor-mediated mechanism underlying the inhibitory 5-HT effect on STN3 SNr EPSCs. Also, unlike the long-lasting complex EPSC that trig- Figure 6 . 5-HT inhibits locally evoked monosynaptic EPSCs in SNr GABA neurons. To avoid activating the apparent recurrent excitation among STN neurons when the stimulating electrode was placed in the STN, in this experiment, the stimulating electrode was placed in the SNr. Paired stimulating pulses were used. The interval between the two pulses was 50 ms. A1, Superimposed averaged EPSCs evoked by the paired pulse stimulation before (black), during (red), and after (blue) 10 M 5-HT application are shown in color. A2, Current traces in A1 are normalized to the peak of the first EPSC in each pair to show clearly that the second EPSC is relatively increased during 10 M 5-HT, leading to increased PPR. B1, Pooled data showing the inhibitory effect of 10 M 5-HT on the peak amplitude of the first of the paired EPSCs in seven SNr GABA neurons. B2, Pooled data showing the increased PPR during 10 M 5-HT in the seven SNr GABA neurons. *p Ͻ 0.05; **p Ͻ 0.01, paired t test. gered ϳ10 spikes within the 100 ms period after stimulation (described in the next section), a monosynaptic EPSC was able to trigger only 1-3 spikes in SNr GABA neurons, indicating the importance of the STN projection and its 5-HT inhibition in the regulation of SNr GABA neuron activity.
Next, we asked this question: How does 5-HT affect a train of synaptic input? To answer this question, we stimulated SNr with a train of 10 pulses with interpulse interval of 50 ms (20 Hz) and examined the effect of 10 M 5-HT on the evoked monosynaptic EPSCs. We made statistical comparisons on these repetitive stimulation-evoked EPSCs using repeated-measures ANOVA. As illustrated in Figure 7 , A-C, under control condition, 20 Hz repetitive stimulation-evoked monosynaptic EPSCs displayed significant activity-dependent depression. Consequently, the ratios of fifth EPSC/first EPSC through tenth EPSC/first EPSC were smaller than the ratio (1.0) of first EPSC/first EPSC (Fig. 7C) . Bath application of 10 M 5-HT induced a global decrease in the peak currents of the EPSC train (n ϭ 8 cells, p Ͻ 0.01, repeatedmeasures ANOVA; Fig. 7 A, B) . The first EPSC in the train was most severely reduced, decreasing from 229.5 Ϯ 58.1 to 98.2 Ϯ 35.5 pA ( p ϭ 0.002, repeated-measures ANOVA, n ϭ 8 cells), a 59% reduction. This led to less variable peaks in the EPSC train. Consequently, the ratios of EPSC n /EPSC 1 increased significantly during bath application of 10 M 5-HT ( p ϭ 0.022, repeatedmeasures ANOVA, n ϭ 8 cells) (Fig. 7C ). For example, under our control condition, the ratio of EPSC 10 /EPSC 1 was 0.63 Ϯ 0.12 and smaller than the ratio (1.0) of EPSC 1 /EPSC 1 ( p ϭ 0.015, repeated-measures ANOVA), indicating that the monosynaptic EPSCs underwent activity-dependent depression, likely due to a decrease in the synaptic vesicle release during repetitive stimulation (Thomson, 2000; Zucker and Regehr, 2002) . During bath application of 10 M 5-HT, there was no difference between the ratios of EPSC 1 /EPSC 1 (1.0) and EPSC 10 /EPSC 1 (1.04 Ϯ 0.28) ( p ϭ 0.891, repeated-measures ANOVA), indicating an equalization of EPSC amplitudes. These results suggested that 5-HT can reduce the intensity of the subthalamonigral excitation by reducing the glutamate release, leading to a more moderate and more even excitatory synaptic transmission during repetitive STN neuron firing.
5-HT and 5HT1B receptor agonist CP93129 inhibit STNtriggered burst firing in SNr GABA neurons
The STN can trigger burst firing in SNr GABA neurons (Shen and Johnson, 2006; Ammari et al., 2010) . Our voltage-clamp data indicated that 5-HT inhibits the STN3 SNr complex EPSCs through the presynaptic 5-HT1B receptors. So we predicted that 5-HT may inhibit STN-triggered burst firing in SNr GABA neurons. As shown in Figure 8 , A and B, bath application of 10 M 5-HT decreased the STN-triggered burst firing frequency in the 100 ms period after the stimulation artifact from 92.63 Ϯ 11.40 to 38.11 Ϯ 5.42 Hz ( p Ͻ 0.01, paired t test, n ϭ 6). This effect was recovered upon washing out 5-HT. At the same time, 10 M 5-HT also significantly increased the spontaneous firing frequency in SNr GABA neurons from the baseline 8.51 Ϯ 0.59 to 13.93 Ϯ 1.86 Hz ( p Ͻ 0.05, paired t test, n ϭ 6) (Fig. 8C) , likely due to 5-HT activating 5-HT2C receptors in SNr GABA neurons (Stanford and Lacey, 1996) . These results indicated that 5-HT inhibited STN-triggered burst firing in SNr GABA neurons while increasing the spontaneous firing frequency that tends to increase the firing regularity in these neurons (Zhou et al., 2008) .
We also tested the effect of the 5-HT1B receptor agonist CP93129 on STN-triggered burst firing in SNr GABA neurons. As illustrated in Figure 9 , A and B, bath application of 10 M CP93129 decreased the average burst firing frequency in the 100 ms period immediately after the stimulation artifact from 88.73 Ϯ 15.91 to 33.26 Ϯ 7.14 Hz ( p Ͻ 0.005, paired t test, n ϭ 6). However, in these same cells, 10 M CP93129 had no effect on the baseline spontaneous firing frequency (11.97 Ϯ 2.26 and 10.59 Ϯ 2.37 Hz for control and 10 M CP93129 respectively, p ϭ 0.28, paired t test, n ϭ 6) (Fig. 9C) . These results indicated that 5-HT1B receptor activation may inhibit STN-triggered burst fir- A, Example traces show STN-triggered burst firing in an SNr GABA neuron under control condition, during bath application of 10 M CP93129, and after washing out CP93129. B, Summary of the inhibitory effect of 10 M CP93129 on the average intraburst firing frequency during the 100 ms immediately following the stimulus artifact in six SNr GABA neurons; 10 M CP93129 significantly inhibited the averaged burst firing frequency. C, Summary of the excitatory effect of 10 M CP93129 on the spontaneous firing frequency in the six same SNr GABA neurons. **p Ͻ 0.01, paired t test.
ing in SNr GABA neurons while sparing the intrinsically generated baseline spontaneous firing in these neurons.
To further test the idea that activation of 5-HT1B receptor on the STN3 SNr axon terminal is mainly responsible for reducing the STN-triggered burst firing in SNr GABA neurons, we locally puffed 1 mM CP93129 to STN and SNr, respectively, using a picospritzer. In STN, the puff pipette was positioned between the two poles of the stimulating electrode such that the ejected drug can quickly reach the tissue being stimulated electrically. In SNr, the puff pipette was positioned ϳ75 m away from the recorded neuron. More details are described in the method section. As shown in Figure 10 , A and B, locally puffed 1 mM CP93129 to STN significantly but modestly reduced the average burst firing rate to 79.5 Ϯ 2.9% of control, a 20% reduction (n ϭ 8, p ϭ 0.002, post hoc Bonferroni test following one-way ANOVA, F (6,43) ϭ 34.9, p Ͻ 0.001). Locally puffed 1 mM CP93129 to SNr significantly decreased the average burst firing rate to 46.3 Ϯ 5.8% of control, a 54% reduction (n ϭ 8, p ϭ 0.000, one-way ANOVA). The inhibitory effect on the average burst firing rate induced by 1 mM CP93129 puffed to SNr is statistically larger than the inhibition induced by 1 mM CP93129 puffed to STN (n ϭ 8, p ϭ 0.00, post hoc Bonferroni test following one-way ANOVA; Fig. 10B ). Similar to the results of bath application of CP93129, locally puffed 1 mM CP93129 to both STN and SNr had no effect on the baseline spontaneous firing (9.2 Ϯ 1.0, 9.4 Ϯ 1.1, and 8.8 Ϯ 0.9 Hz for control; locally puffed 1 mM CP93129 to STN and locally puffed 1 mM CP93129 to SNr, respectively; n ϭ 8, one-way ANOVA: F (6,43) ϭ 0.63, p ϭ 0.71). Furthermore, increasing CP93129 to 2 mM in the puff pipette did not increase its inhibitory effect in STN or SNr, whereas decreasing CP93129 to 0.2 mM led to a smaller effect. Thus, puff applied 1 mM CP93129 apparently saturated the 5-HT1B receptors in STN and SNr (data not shown). To rule out any potential nonspecific effect of puff application, we also puffed the normal extracellular solution or the ACSF (used to dissolve CP93129) to STN and SNr during the recording of five of the eight SNr neurons described above. As shown in Figure 10 , A-C, locally puffed ACSF to STN or SNr had no effect on both averaged burst firing and spontaneous firing rate (n ϭ 5, one-way ANOVA, p ϭ 1.000 for both averaged burst firing and spontaneous firing). Together, these results indicate that activation of 5-HT1B receptor on the STN3 SNr axon terminal is mainly responsible for reducing the STN-triggered burst firing in SNr GABA neurons.
Endogenous 5-HT effect on STN3 SNr complex EPSCs and STN-triggered burst firing in SNr GABA neurons
Since the SNr receives a dense 5-HT innervation (Fig. 11A) , we reasoned that 5-HT axons in our sagittal brain slices may release sufficient amounts of 5-HT that in turn activate presynaptic 5-HT1B receptors and inhibit glutamate release from the STN3 SNr projection. To test this idea, we examined the effect of the 5-HT1B receptor antagonist NAS-181. As illustrated in Figure 11 , B and C, bath application of 10 M NAS-181 increased the STN3 SNr complex EPSC area by 20.3 Ϯ 3.2% ( p Ͻ 0.05, paired t test, n ϭ 5 cells), and the effect was recovered upon washing out NAS-181. Equally important, under current-clamp recording mode, bath application of 10 M NAS-181 increased STN stimulation-triggered burst firing frequency in the 100 ms period immediately after the stimulation to 95.4 Ϯ 10.0 Hz from 75.6 Ϯ 7.8 Hz under control ( p Ͻ 0.05, paired t test, n ϭ 6; Fig.  12 A, B) . The spontaneous spike firing was not affected, remaining ϳ10 Hz (Fig. 12 A, C) , consistent with the idea that the spontaneous baseline spike firing was intrinsically generated and not driven by synaptic inputs (Atherton and Bevan, 2005; Zhou and Lee, 2011) and that 5-HT1B receptors are on STN3 SNr axon terminals as indicated by our data presented in the preceding sections. These results indicate that the STN3 SNr glutamatergic transmission is inhibited by endogenous 5-HT in the SNr. Figure 10 . 5-HT1B receptor agonist CP93129 inhibits STN-triggered burst firing in SNr GABA neurons more strongly when applied locally to SNr than to STN. A, Example traces show STN-triggered burst firing in an SNr GABA neuron under control condition, locally puffed ACSF, or 1 mM CP93129 to STN or SNr, locally and washing out CP93129. B, Pooled data showing the effect of locally puffed ACSF or 1 mM CP93129 to SNr or STN on STN-triggered burst firing rate in SNr GABA neurons. The averaged burst firing rates in different treatment conditions were normalized to the averaged burst firing rate in control. Locally puffed 1 mM CP93129 to SNr reduced the averaged bursting firing rate to a larger extent than did locally puffed 1 mM CP93129 to STN (n ϭ 8, p ϭ 0.000), while locally puffed ACSF to STN or SNr had no effect on the burst firing rate (n ϭ 5, p ϭ 1.000). C, Summary of the lack of effect of locally puffed ACSF (n ϭ 5, p ϭ 1.000) or 1 mM CP93129 (n ϭ 8, p ϭ 1.000) to STN or SNr on the spontaneous firing frequency in the same SNr GABA neurons. Post hoc Bonferroni test following one-way ANOVA was used for statistical comparison.
Discussion
The main findings of this study are that 5-HT may inhibit or gate the STN3 SNr glutamatergic projection by reducing glutamate release via presynaptic 5-HT1B receptors, consequently decreasing STNtriggered burst firing and global firing intensity in SNr projection neurons. These findings advance our understanding of this crucial excitatory drive known to be important to the function of the basal ganglia and movement disorders such as PD.
Presynaptic 5-HT1B receptor-mediated gating of the STN3 SNr glutamatergic projection Anatomical studies have provided strong evidence that STN neurons project directly or monosynaptically to the SNr (Kita and Kitai, 1987; Smith et al., 1990; Bevan et al., 1994; Sato et al., 2000; . There is also evidence that STN may project to the pedunculopontine nucleus (PPN), which in turn projects back to STN, though the neurochemical nature of this projection is not clear (Hammond et al., 1983; Jackson and Crossman, 1983; Kita and Kitai, 1987; Smith et al., 1990; Martinez-Gonzalez et al., 2011) . The relatively long distance STN projection to PPN was likely to be severely cut in our slice preparation. Furthermore, in a subset of our experiments, cutting off PPN caused no difference in STN-evoked EPSCs in SNr GABA neurons. Studies have also established that STN neurons and thus STN efferents use glutamate as their neurotransmitter (Smith and Parent, 1988; Parent and Hazrati, 1995; Shen and Johnson, 2006; Ammari et al., 2010) . Therefore, when we stimulated STN in our brain slice preparation, we activated predominately the STN3 SNr monosynaptic glutamatergic projection and intra-STN polysynaptic recurrent glutamatergic excitation.
The importance of STN in basal ganglia physiology and pathophysiology is demonstrated by that fact that STN is the most common target of deep brain stimulation, which has a dramatic therapeutic effect on the motor symptoms of PD and related motor disorders (Perlmutter and Mink, 2006; Gubellini et al., 2009; Lozano et al., 2010) . Therefore, understanding the endogenous mechanisms that regulate the STN output is essential. In our present study, we found that 10 M 5-HT reduced the area or charge transfer of the complex STN3 SNr EPSC by 66% (Fig.  2) . The 5-HT1B receptor agonist CP93129 mimicked and 5-HT1B antagonist NAS-181 blocked this 5-HT effect, whereas ligands for 5-HT1A receptors were without effect (Figs. 3, 4) . Further, 10 M 5-HT reduced mEPSC frequency by 53% and the monosynaptic STN3 SNr EPSC amplitude by 56% while increasing PPR by 46% (Figs. 5, 6 ). Thus, the majority (80 -85%) of 5-HT inhibition of the STN3 SNr complex EPSCs was mediated by presynaptic 5-HT1B receptors in STN3 SNr axon terminals, while the 15-20% of the 5-HT inhibition was likely due to 5-HT1B-mediated inhibition of intra-STN recurrent excitation. This conclusion was further supported by our observation that 5-HT1B agonist CP93129 puffed to SNr reduced the averaged burst firing rate to a larger extent than CP93129 puffed to STN (a 54% reduction vs a 20% reduction) (Fig. 7) . Our present observations and interpretation are fully consistent with anatomical studies on 5-HT1B receptor expression. These studies, using mRNA in situ hybridization, receptor ligand binding, receptor immunostain, and ultrastructural techniques, have established that the expression of 5-HT1B receptors is the strongest in the SNr and a few other brain areas (Bruinvels et al., 1993 (Bruinvels et al., , 1994 Boschert et al., 1994; Sari et al., 1999; Riad et al., 2000; Sari, 2004) . These studies also indicate that 5-HT1B receptors are located in axon terminals and preterminal areas, but not in somatodendritic areas. Lesion of the striatum reduced the 5-HT1B receptor level in the SNr by ϳ50%, indicating that 5-HT1B receptors are on the striatonigral axons (Stanford and Lacey, 1996; Sari et al., 1999) and also other afferents to the SNr (Sari et al., 1999) . One afferent that may express 5-HT1B receptors is the STN3 SNr glutamatergic projection. Like striatonigral neurons, STN neurons express a high level of 5-HT1B mRNA but not 5-HT1B receptors, a typical mismatch of 5-HT1B mRNA level and 5-HT1B receptor level at the cell body (Maroteaux et al., 1992; Boschert et al., 1994; Sari, 2004) . Although direct ultrastructural evidence showing 5-HT1B receptors being at STN3 SNr axon terminals is not yet available, we speculate that like striatonigral neurons, STN neurons may express high levels of 5-HT1B receptors at their axon terminals to reduce the release of glutamate. This conclusion, coupled with the fact that the SNr has an intense 5-HT innervation (Moukhles et al., 1997; Parent et al., 2011) , leads us to speculate that in intact animals, the endogenous 5-HT in the STN-SNr region affects STN3 SNr glutamatergic synaptic transmission predominantly by directly inhibiting glutamate release at the axon terminal. The contribution from 5-HT regulation of STN neuron somata may be relatively small.
Our present results that 5-HT1B receptor activation reduces glutamate release at STN3 SNr axon terminals are consistent with literature reports that 5-HT1B receptors are coupled to G i/o G-protein, leading a reduction of the intracellular cAMP level (Bockaert et al., 2006; Hannon and Hoyer, 2008; Millan et al., 2008) . A decreased cAMP level may reduce neurotransmitter release (Yao and Sakaba, 2010) by either decreasing Ca 2ϩ influx or decreasing the efficacy of presynaptic secretory machinery (Chen and Regehr, 1997; Kaneko and Takahashi, 2004) . Our results are also consistent with reported presynaptic 5-HT1B receptor inhibition of glutamate release at other synapses (Singer et al., 1996; Li and Bayliss, 1998; Muramatsu et al., 1998; Pickard et al., 1999; Morikawa et al., 2000; Laurent et al., 2002; Bouryi and Lewis, 2003; Mizutani et al., 2006) . The lack of effect of 5-HT1A receptor ligands in our present study is consistent with anatomical findings that indicated a lack of detectable 5-HT1A receptor expression in the SNr (Kia et al., 1996; Riad et al., 2000) . Also, despite the reported expression of 5-HT4 and 5-HT2C receptors in the STN (Pompeiano et al., 1994; Xiang et al., 2005; Shen and Johnson, 2007 ), we did not detect any significant effect of 5-HT2C and 5-HT4 receptor agonists on STN3 SNr complex EPSCs (data not shown). These results suggest that 5-HT2C and 5-HT4 receptors may be expressed at relatively low levels in the STN neurons (Clemett et al., 2000) that do not produce detectable effects on the interaction among STN neurons and thus no effect on the generation of the complex EPSCs, under our experimental conditions. Together, our results indicate that presynaptic 5-HT1B receptors gate the STN3 SNr glutamatergic projection.
5-HT inhibits STN-triggered burst firing in SNr GABA neurons: functional implications
In this study, we found that focal stimulation in the STN evokes long-lasting complex EPSCs that trigger bursts of high-frequency spiking or burst firing in SNr GABA neurons (Figs. 8, 9) , showing a powerful excitatory influence of the glutamatergic STN projection on SNr GABA neurons. This finding is consistent with previous studies that described similar STN neuron recurrent excitation-triggered complex EPSCs and burst firing in SNr GABA neurons (Shen and Johnson, 2006; Ammari et al., 2010) . Equally important, we also found that 5-HT and 5-HT1B receptor agonist CP93129 inhibited STN-triggered burst firing . This inhibitory effect was likely the result of presynaptic 5-HT1B receptors inhibiting glutamate release, as discussed in the preceding section. Thus, endogenous 5-HT, via presynaptic 5-HT1B receptors on STN-SNr axon terminals, may dampen excitatory inputs from the STN and reduce the burstiness in the spike firing in SNr GABA neurons that is known to have potential pathophysiological relevance (Zhou and Lee, 2011) .
Given the known importance of the STN in motor control and PD pathophysiology (Obeso et al., 2008; , the presynaptic 5-HT inhibition of the STN glutamatergic projection described here may have critical functional implications. First, our finding provides a cellular substrate to the view that a key function of the brain 5-HT system is to facilitate motor activity (Jacobs and Fornal, 1999; Jacobs et al., 2002), because 5-HT inhibition of the STN3 SNr glutamatergic projection may lead to a relative disinhibition of the thalamocortical motor circuit and thus promote movements. The second implication is the potential contribution of this presynaptic 5-HT1B receptor-mediated mechanism to the pathophysiology of PD. A well established neurophysiological abnormality in PD models and PD patients is that the STN neurons fire at increased frequencies and with increased bursting, causing heightened and abnormal STN3 SNr glutamatergic transmission (Steigerwald et al., 2008; Lozano et al., 2010; Wichmann and Dostrovsky, 2011; Wichmann et al., 2011) . This causes the basal ganglia GABA output neurons in the SNr to increase their spike frequency and burst firing that in turn result in an abnormal inhibition of the thalamocortical motor circuit and parkinsonian motor deficits. Postmortem studies have shown a substantial degeneration of the 5-HT system in PD brains, indicating a potentially important role of the 5-HT system in the pathophysiology of PD (Braak et al., 2004; Kish et al., 2008; Huot et al., 2011) . A loss of 5-HT in the SNr in the PD brain may weaken the inhibitory 5-HT control over the STN3 SNr projection, potentially leading to increased firing with abnormal patterns in SNr GABA neurons and eventually motor deficits. Indeed, a recent study has demonstrated that 5-HT depletion increased burst firing in SNr GABA neurons (Delaville et al., 2012) . Our results also indicate that the presynaptic 5-HT1B receptors on the STN3 SNr axon terminals may be an important target for treating PD motor deficits.
